VERAXA Biotech AG (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as its new chief financial officer, effective immediately. The move is expected to bolster the company's capital strategy and support its ongoing development of proprietary BiTAC(R) technology and oncology pipeline.
Willener brings more than three decades of international financial leadership experience, spanning global capital markets, investment banking, corporate finance, asset management, and strategic leadership. He will report directly to CEO and Co-Founder Christoph Antz, Ph.D., and will be instrumental in guiding the company's financial planning and strategic opportunities as it advances its clinical programs.
Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in 2025. In that role, he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management.
This appointment comes at a critical time for VERAXA as it accelerates the development of its BiTAC(R) platform, which is designed to create bispecific T cell engagers, bispecific ADCs, and other innovative antibody formats. The company's pipeline is focused on addressing significant unmet needs in oncology, and the addition of a seasoned financial executive is expected to enhance its ability to secure funding and forge strategic partnerships.
The news is important because it signals VERAXA's commitment to strengthening its financial leadership as it moves toward clinical development. With Willener's extensive background in capital markets and corporate finance, the company is better positioned to navigate the complexities of funding advanced therapeutic research and to maximize shareholder value.
Investors and industry observers will be watching to see how Willener's expertise translates into tangible progress for VERAXA's pipeline. The company's innovative approach to antibody-based therapies has the potential to offer new treatment options for cancer patients, and having a strong financial leader at the helm is crucial for translating scientific breakthroughs into marketable therapies.
For more information about VERAXA Biotech and its latest updates, visit the company's newsroom at http://nnw.fm/VRXA.
